FDA Grants Rare Pediatric Disease Designation to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II)

ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq: RGNX ), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-121, REGENXBIO’s investigational gene therapy product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II).

"Along with RGX-111 for the treatment of MPS I, this is our second MPS program to achieve a Rare Pediatric Disease Designation and builds upon the Orphan Drug Designation granted to RGX-121 at the end of 2015 by the FDA, underscoring the therapy’s potential to provide meaningful benefit to children struggling with this severely debilitating disease,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “Both of these programs use our NAV AAV9 vector and we plan to file Investigational New Drug applications for RGX-111 and RGX-121 in the first half of 2017. We look forward to working with the FDA to advance this platform of gene therapies for MPS to patients in need.”

The FDA defines a "rare pediatric disease" as a disease that affects fewer than 200,000 individuals in the U.S., primarily aged from birth to 18 years. Under the FDA's Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives an approval of a new drug application or biologics license application for a rare pediatric disease may be eligible for a voucher, which can be redeemed to obtain priority review for any subsequent marketing application and may be sold or transferred.

MPS II, also known as Hunter syndrome, is a rare, X-linked recessive disease caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase (IDS). Approximately 500 to 1,000 individuals with MPS II are estimated to be born each year worldwide. In severe forms of the disease, early developmental milestones may be met, but developmental delay is readily apparent by 18 to 24 months. Developmental progression begins to plateau between three and five years of age, with regression reported to begin around six and a half years. RGX-121 uses an AAV9 vector to deliver the IDS gene to the central nervous system.

About REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of March 31, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 28 product candidates for a variety of diseases, including five internally developed candidates and 23 partnered candidates developed by REGENXBIO's licensees.

Forward Looking Statements

This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, REGENXBIO's research, development and regulatory plans for RGX-111, RGX-121 and other gene therapies. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could cause actual results to differ materially from those projected by such forward-looking statements. All of REGENXBIO’s development timelines could be subject to adjustment depending on recruitment rate, regulatory agency review and other factors that could delay the initiation and completion of clinical trials. Meaningful factors which could cause actual results to differ include, but are not limited to, the timing of enrollment, commencement and completion of REGENXBIO's clinical trials; the timing and success of preclinical studies and clinical trials conducted by REGENXBIO, its development partners and its NAV Technology Licensees; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize REGENXBIO's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing REGENXBIO's product candidates; REGENXBIO's ability to obtain and maintain intellectual property protection for our product candidates and technology; trends and challenges in REGENXBIO's business and the markets in which REGENXBIO operates; REGENXBIO's ability to attract or retain key personnel; the size and growth of the potential markets for REGENXBIO's product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of REGENXBIO's product candidates; REGENXBIO's ability to establish and maintain development partnerships, including those with NAV Technology Licensees; REGENXBIO's expenses and revenue, the sufficiency of REGENXBIO's cash resources and needs for additional financing, regulatory developments in the United States and foreign countries, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are available on the SEC's website at www.sec.gov . Additional factors may be set forth in those sections of REGENXBIO's Form 10-Q for the quarter ended June 30, 2016, to be filed with the SEC in the third quarter of 2016. In addition to the risks described above and in REGENXBIO's filings with the SEC, other unknown or unpredictable factors also could affect REGENXBIO's results. There can be no assurance that the actual results or developments anticipated by REGENXBIO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, REGENXBIO. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. REGENXBIO cautions investors not to rely too heavily on the forward-looking statements REGENXBIO makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). REGENXBIO undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investors Elizabeth Broder, 646-378-2945 ebroder@troutgroup.com Media Laura Bagby, 312-448-8098 lbagby@6degreespr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 27

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 107

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 190

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 64

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 119

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 152

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 41

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading

Top 5 Most Recently Viewed Articles

Huawei's Innovative Energy Solutions Drive Renewable Power Growth

Updated Category News Views 184

Transforming Energy Solutions with Huawei Digital Power At a prominent event in Germany, Huawei Digital Power made waves by showcasing cutting-edge solar and energy storage technologies. The company hosted an important launch event under the title "Smart PV & ESS: Powering a Grid Forming Future," emphasizing their commitment to advancing renewable energy solutions. With...

Continue Reading
Carlyle Credit Income Fund's NAV Insights and Latest Developments

Updated Category News Views 225

Understanding Carlyle Credit Income Fund's Latest NAV Report Carlyle Credit Income Fund (NYSE: CCIF) has recently unveiled its unaudited net asset value (NAV) per common share, reporting this figure as $7.64. This information was shared through a filing with the Securities and Exchange Commission, indicating the fund's current fiscal status. The announcement is important...

Continue Reading
Tuya Inc. to Announce Q4 and Fiscal Year 2025 Results Soon

Updated Category News Views 140

Tuya Inc. to Release Financial Results for Q4 and Fiscal Year 2025 Tuya Inc. (NYSE: TUYA), a prominent AI cloud platform service provider, has announced that it will share its fourth quarter and preliminary fiscal year 2025 financial results shortly after the market closes during the first week of March. This is a significant event for the company as it highlights the...

Continue Reading
Geopolitical Tensions Influence Oil Prices: Market Insights

Updated Category News Views 154

Current Oil Market Dynamics Amid Global Tensions Crude prices have shown significant resilience following earlier losses, positioning themselves for a potential third consecutive day of gains. As geopolitical tensions continue to escalate, the latest developments in the Middle East are fueling market reactions. Iran's Potential Military Actions and Market Implications...

Continue Reading
Antimony Market Growth: A Multi-Billion Dollar Future Ahead

Updated Category News Views 221

The Rising Antimony Market: A New Era of Opportunities Antimony minerals, primarily sourced from stibnite and its various forms, play a crucial role in multiple industries due to their unique properties such as flame retardancy and alloy formation. As societies continue to focus on enhancing safety in various applications, particularly in construction and automotive, the...

Continue Reading